Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

@article{Mikhail2008IncretinMA,
  title={Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.},
  author={Nasser E Mikhail},
  journal={Expert opinion on investigational drugs},
  year={2008},
  volume={17 6},
  pages={845-53}
}
BACKGROUND Exenatide is an incretin mimetic, while sitagliptin and vildagliptin are incretin enhancers used as adjunctive therapy in patients with type 2 diabetes failing oral agents. Sitagliptin and vildagliptin can also be used as monotherapy in patients with type 2 diabetes uncontrolled by diet. OBJECTIVE To provide a critical review of clinical trials of exenatide, sitagliptin and vildagliptin. METHOD Review of Phase III clinical trials based on Medline search published up to April 2008… CONTINUE READING